Kevzara (sarilumab)

€1,696.25
In stock
SKU
Kevzara (sarilumab)

How to buy Kevzara (sarilumab): You can order Kevzara (sarilumab) from TheSocialMedwork if the drug has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.

Rheumatology Rheumatoid Arthritis
Marketing Authorisation Holder Sanofi - Aventis Groupe
Mode of Action Interleukin-6 (IL-6) receptor antagonist
Administration subcutaneous
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA
Package 2 Syringes

What is Kevzara (sarilumab) for?

Kevzara (sarilumab) is indicated for the treatment of patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs)1.

How does Kevzara (sarilumab) work?

Kevzara (sarilumab) is a human monoclonal antibody  — an interleukin-6 (IL-6) receptor antagonist. IL-6 is a cytokine — a small protein involved in the communication among cells2 — that, in excess and over time, can contribute to the inflammation associated with rheumatoid arthritis. Sarilumab binds to the interleukin-6 receptor (IL-6R) and has been shown to inhibit IL-6R mediated signaling3.

Where has Kevzara (sarilumab) been approved?

Kevzara (sarilumab) was approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more DMARDs, such as methotrexate (MTX)1 by:

  • FDA (USA) on May 22, 20173
  • EMA (EU) on June 23, 20175

How is Kevzara (sarilumab) taken?

Kevzara (sarilumab) may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs.

The standard dosage is:

  • 200 mg once every two weeks, administered as a subcutaneous injection

  • Dose modification might be considered for certain patients

  • Sarilumab is not recommended in patients with certain conditions (ANC less than 2000/mm3, platelets less than 150,000/mm3 or liver transaminases above 1.5 times ULN).

Complete information about sarilumab dosage and administration can be found in the resources section.

Consult your treating doctor for personalised dosing.

Are there any known side effects of Kevzara (sarilumab)?

Patients treated with Kevzara (sarilumab) are at increased risk of developing serious infections that may lead to hospitalization or death.

The most common adverse reactions (incidence of at least 3%) are3:

  • neutropenia
  • increased ALT (alanine aminotransferase)
  • injection site erythema
  • upper respiratory infections
  • urinary tract infections.
More Information
Working ingredient sarilumab
Shipping method Cold chain (temperature controlled)
Package 2
Therapeutic Area Rheumatology
Rheumatology Rheumatoid Arthritis
Indication Moderately to severely active rheumatoid arthritis
Administration subcutaneous
Mode of Action Interleukin-6 (IL-6) receptor antagonist
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA
Marketing Authorisation Holder Sanofi - Aventis Groupe

The approvals were based on 2 randomised, double-blind, placebo-controlled multicentre studies (MOBILITY and TARGET) involving 1,197 and 546 adults1.

An important measure in patients with rheumatoid arthritis is the ACR 20, 50 or 70 which is a criteria to measure the improvement of patients of 20%, 50% or 70% based on the following measures: swollen joint count, tender joint count, patient assessment of global status, acute phase reactant (dramatic increase in hepatic synthesis of plasma proteins which accompanies acute phases of tissue injury and inflammation), health professional assessment of global status, physical function, and pain4.

Mobility Study

The MOBILITY group of patients had moderately to severely active rheumatoid arthritis and had an inadequate clinical response to methotrexate (MTX). Patients received subcutaneous sarilumab 200 mg, sarilumab 150 mg, or placebo every two weeks with concomitant MTX. After week 16, patients with an inadequate response could have been rescued with sarilumab 200 mg every two weeks1.

In the MOBILITY study, treatment with Kevzara plus MTX reduced signs and symptoms, improved physical function, and demonstrated significantly less radiographic progression of structural damage, compared to placebo plus MTX3.

At 24 weeks, 66% of the patients treated with Kevzara  200 mg, achieved ACR20, compared with 58% of patients treated with Kevzara 150 mg, and 33% of those on placebo3.

Target Study

The TARGET group of patients had moderately to severely active rheumatoid arthritis and had an inadequate clinical response or were intolerant to one or more TNF-α antagonists. Patients received subcutaneous sarilumab 200 mg, sarilumab 150 mg, or placebo every two weeks with concomitant conventional DMARD(s) (MTX, sulfasalazine, leflunomide, and/or hydroxychloroquine). After week 12 in Study 2, patients with an inadequate response could have been rescued with sarilumab 200 mg every two weeks1.

In the TARGET study, treatment with Kevzara (sarilumab) plus DMARD reduced signs and symptoms and improved physical function, compared to placebo plus DMARD3. At 24 weeks, 61% of patients treated with Kevzara (sarilumab) plus DMARD achieved an ACR20 response, compared with 56% of the patients on sarilumab 150 mg, and 34% of those on placebo3.

Shipping Type Cold Chain
Shipping method Cold chain (temperature controlled)
Dynamic Weight No
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Our Support team is available between
9:00–18:00 Central European Time, Monday to Friday.

 

Don't speak English? We also speak
Afrikaans, Armenian, Bosnian, Bulgarian, Dutch, German, Italian, Lithuanian, Mandarin, Portuguese, Russian, Serbian, Slovenian, Spanish and Turkish

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 

The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

You can order and receive your
medicine in 5 simple steps

1

Talk to your doctor

2

Place order
and send
prescription

3

Pay for order

4

Check documents
for delivery

5

Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.